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Abstract
Introduction We recently described the ability of retinoid X
receptor (RXR) ligand LG100268 (LG268) to inhibit interleukin1-beta (IL-1-)-driven matrix metalloproteinase-1 (MMP-1) and
MMP-13 gene expression in SW-1353 chondrosarcoma cells.
Other investigators have demonstrated similar effects in
chondrocytes treated with rosiglitazone, a ligand for peroxisome
proliferator-activated receptor-gamma (PPAR), for which RXR
is an obligate dimerization partner. The goals of this study were
to evaluate the inhibition of IL-1--induced expression of MMP1 and MMP-13 by combinatorial treatment with RXR and
PPAR ligands and to investigate the molecular mechanisms of
this inhibition.
Methods We used real-time reverse transcription-polymerase
chain reaction to measure LG268- and rosiglitazone-mediated
inhibition of MMP gene transcription in IL-1--treated SW-1353
chondrosarcoma cells. An in vitro collagen destruction assay
was a functional readout of MMP collagenolytic activity.
Luciferase reporter assays tested the function of a putative
regulatory element in the promoters of MMP-1 and MMP-13,
and chromatin immunoprecipitation (ChIP) assays detected
PPAR and changes in histone acetylation at this site. Posttranslational modification of RXR and PPAR by small ubiquitinlike modifier (SUMO) was assayed with immunoprecipitation
and Western blot.

Results Rosiglitazone inhibited MMP-1 and MMP-13
expression in IL-1--treated SW-1353 cells at the mRNA and
heterogeneous nuclear RNA levels and blunted IL-1--induced
collagen destruction in vitro. Combining LG268 and
rosiglitazone had an additive inhibitory effect on MMP-1 and
MMP-13 transcription and collagenolysis. IL-1- inhibited
luciferase expression in the MMP reporter assay, but
rosiglitazone and LG268 had no effect. ChIP indicated that
treatment with IL-1-, but not LG268 and rosiglitazone,
increased PPAR at the proximal promoters of both MMPs.
Finally, rosiglitazone or LG268 induced 'cross-SUMOylation' of
both the target receptor and its binding partner, and IL-1--alone
had no effect on SUMOylation of RXR and PPAR but
antagonized the ligand-induced SUMOylation of both receptors.

Conclusions The PPAR and RXR ligands rosiglitazone and
LG268 may act through similar mechanisms, inhibiting MMP-1
and MMP-13 transcription. Combinatorial treatment activates
each partner of the RXR:PPAR heterodimer and inhibits IL-1-induced expression of MMP-1 and MMP-13 more effectively
than either compound alone. We conclude that the efficacy of
combined treatment with lower doses of each drug may
minimize potential side effects of treatment with these
compounds.

AP-1: activator protein-1; ChIP: chromatin immunoprecipitation; DMEM: Dulbecco's modified Eagle's medium; DR-1: direct repeat-1; ECM: extracellular matrix; FBS: fetal bovine serum; FXR: farnesoid X receptor; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; HA: hemagglutinin; HAPPAR: hemagglutinin-tagged peroxisome proliferator-activated receptor-gamma; HAT: histone acetyltransferase; HBSS: Hanks' balanced salt solution; HDAC: histone deacetylase; hnRNA: heterogeneous nuclear RNA; IL-1: interleukin-1-beta; IP: immunoprecipitation; LG268: LG100268; LH:
lactalbumin hydrosylate; LXR: liver X receptor; MMP: matrix metalloproteinase; MMPI: matrix metalloproteinase inhibitor; MSS: musculoskeletal syndrome; NHR: nuclear hormone receptor; OA: osteoarthritis; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PPAR: peroxisome
proliferator-activated receptor-gamma; PPRE: peroxisome proliferator-activated receptor-gamma response element; RA: rheumatoid arthritis; RT:
reverse transcription; RXR: retinoid X receptor; SUMO: small ubiquitin-like modifier; TCA: trichloracetic acid.
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Introduction
The matrix metalloproteinases (MMPs) are a family of zincdependent endopeptidases responsible for the degradation of
extracellular matrix (ECM) components. While low levels of
these enzymes are required for the homeostatic ECM turnover
seen in wound healing, angiogenesis, and development, high
levels have been implicated in the pathology of atherosclerosis, tumor metastasis, and the arthritides. In the case of osteoarthritis (OA) and rheumatoid arthritis (RA), members of the
collagenase subgroup of the MMPs, specifically MMP-1 and
MMP-13, are particularly important in the progression of joint
disease [1,2]. The ability to cleave the collagen triple helix is
unique to the collagenases, and the overexpression of MMP-1
and MMP-13 in chondrocytes in response to proinflammatory
cytokines such as interleukin-1-beta (IL-1) and tumor necrosis factor-alpha is critical in the pathogenesis of OA and RA
[1].
Many efforts to design small-molecule inhibitors of MMP activity (MMPIs) have succeeded in creating potent compounds;
however, due to the highly conserved nature of the catalytic
domain among family members, these compounds demonstrate significant inhibitory efficacy against multiple MMPs [3].
This lack of specificity has been identified as the likely cause
of the debilitating side effects observed in clinical trials with
these compounds which presented as a chronic musculoskeletal syndrome (MSS) that was characterized by reduced
mobility with joint pain and edema due to tendonitis and inflammation [4-6]. The root cause of the MSS is thought to be the
disruption of normal connective tissue turnover, secondary to
the inhibition of multiple MMPs [7]. Unfortunately, the MSS
has continued to hinder many newly developed MMPIs, resulting in the discontinuation of multiple clinical trials [8], although
promising results with MMP-specific compounds are emerging [9]. Specific inhibition of MMP gene synthesis is an alternative strategy for counteracting the overexpression of MMPs
involved in particular diseases. Although many MMP promoters share similarities, particular variations in MMP promoter
structure and in the signaling pathways required for their
expression may make it possible to target certain family members with specific ligands.
Peroxisome proliferator-activated receptor-gamma (PPAR) is
a nuclear hormone receptor (NHR) initially recognized as a
regulator of genes active in adipogenesis and insulin sensitivity [10]. PPAR forms an obligate heterodimer with the retinoid
X receptor (RXR:PPAR) that binds to direct repeat-1 (DR-1)
motifs, known as PPAR response elements (PPREs), in the
promoter DNA of regulated genes [11]. NHRs are typically
thought to exert their transcriptional regulatory effects through
interaction with coregulatory complexes, which modify the
local chromatin environment via multiple mechanisms, includ-
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ing the enzymatic activity of histone deacetylases (HDACs)
and histone acetyltransferases (HATs) [12]. HDAC activity
results in a decrease in histone acetylation and a subsequent
decrease in transcriptional activity, whereas HAT activity leads
to an increase in histone acetylation and a subsequent
increase in transcriptional activity [13].
Recent work has identified an anti-inflammatory role for PPAR
in chondrocytes when the receptor is activated by ligands
such as the thiazolidinedione compound rosiglitazone and the
prostaglandin 15-Deoxy-12,14-prostaglandin J2 [2,14-16].
Notably, this anti-inflammatory effect of PPAR ligands
extends to the inhibition of IL-1-induced expression of MMP1 and MMP-13 in rabbit chondrocytes [2,17,18], and administration of these compounds blunts the development of joint
disease in animal models of arthritis [18,19]. François and colleagues [17] have proposed a mechanism to explain rosiglitazone-mediated inhibition of IL-1-induced expression of rabbit
MMP-1 that involves binding of the RXR:PPAR heterodimer
to a degenerate DR-1 site in the proximal (approximately -72
base pairs) region of the rabbit MMP-1 promoter. This DR-1
site overlaps a binding site for the transcription factor activator
protein-1 (AP-1), which is largely responsible for the proinflammatory cytokine-induced upregulation of MMP-1 [20]. In this
competitive binding model, binding of the RXR:PPAR heterodimer to the DR-1 element precludes binding of AP-1 proteins to its site and thereby antagonizes the expression of
MMP-1. François and colleagues [17] also identified a similar
degenerate DR-1/AP-1 site in the promoters of human MMP1, MMP-9, and MMP-13, although the function of this site has
not been experimentally verified in the human genes.
Previous work by our laboratory has shown that LG100268
(LG268), a ligand specific for RXR, inhibits IL-1-induced
MMP-1 and MMP-13 transcription in the SW-1353 human
chondrosarcoma cell line and is associated with a decrease in
histone acetylation proximal to the transcription start site in the
MMP-1 and MMP-13 promoters [21]. While RXR is an obligate dimer partner for a number of other NHRs, including retinoic acid receptors, thyroid receptor, vitamin D receptor,
PPARs, liver X receptors (LXRs), and farnesoid X receptor
(FXR) [22], the ligand LG268 activates only a subset of the
RXR catalog of partners, including RXR:FXR, RXR:LXR,
RXR:PPAR, and RXR:PPAR heterodimers, as well as RXR
homodimers [23-25]. Of these dimers, only RXR:PPAR,
RXR:PPAR, and RXR homodimers bind to the DR-1 element
[11], suggesting that all or any of these three dimers may be
responsible for mediating the inhibitory effect of LG268 on
MMP-1 and MMP-13. However, since PPAR-specific, but
not PPAR, ligands block MMP-1 and MMP-13 gene expression, RXR:PPAR heterodimers as well as RXR homodimers
may be mediating this suppression [2,18,26].
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Recent investigations into the mechanisms by which PPAR
inhibits the expression of genes involved in inflammation have
identified a molecular pathway of ligand-dependent conjugation of the small ubiquitin-like modifier (SUMO) to lysines in the
PPAR receptor [14,27]. This SUMO-conjugated form of
PPAR then binds to corepressor complexes containing
HDAC activity and to other promoter-bound proteins. This
anchors the corepressors and prevents their release upon
proinflammatory stimulation, thereby blocking recruitment of
coactivator complexes with HAT activity. The presence of multiple functional SUMOylation sites (SUMO consensus
sequence =  KXE/D, where  is a hydrophobic amino acid,
X is any amino acid, and K is the specific SUMOylation target)
within PPAR has been confirmed [14,27], and Floyd and colleagues [27] describe multiply SUMOylated forms of PPAR.
Pascual and colleagues [14] demonstrate that SUMOylation
at different sites confers different modifications of receptor
activity and identify K365 as the SUMOylation site required for
transrepression of inflammatory genes by PPAR. SUMOylation of RXR has also been reported [28].
We hypothesized that, because LG268 and PPAR ligands
target the same NHR complex and have similar inhibitory
effects on MMP production, both ligands may be activating
similar mechanisms to inhibit MMP gene expression. The competitive binding model implicates competition for binding to
the degenerate DR-1 site between RXR:PPAR and AP-1 proteins as a possible mechanism for rosiglitazone-mediated inhibition of MMP-1 [17]. In addition, we hypothesized that
LG268, as a ligand for RXR, may also induce increased binding of the heterodimer to the DR-1 site and that combination
treatment with both ligands would further increase binding to
the DR-1 site since both NHRs would be liganded. As a result,
combined treatment should lead to greater inhibition of MMP1 and MMP-13 gene expression compared with either compound alone. In this paper, we demonstrate that combined
treatment with the RXR ligand LG268 and the PPAR ligand
rosiglitazone suppresses MMP-1 and MMP13 gene expression more effectively than either compound alone. In addition,
we document that this inhibition is transcriptionally mediated
and involves genetic and epigenetic mechanisms but does not
appear to involve competitive binding between RXR:PPAR
and AP-1 at the DR-1/AP-1 element.

Materials and methods
Cell culture
SW-1353 human chondrosarcoma cells were obtained from
the American Type Culture Collection (Manassas, VA, USA).
These cells were propagated at 37°C with 5% CO in Dulbecco's modified Eagle's medium (DMEM) (Mediatech, Inc.,
Manassas, VA, USA) containing 10% fetal bovine serum
(FBS) (HyClone, Logan, UT, USA), 100 U/mL penicillin, 100
L/mL streptomycin, and 2 mM glutamine. Cells were washed
three times with Hanks' balanced salt solution (HBSS) and
passaged 1:10 using 0.25% trypsin (Mediatech, Inc.). Experi-

ments were performed with cells from passages 10 to 30, and
subsequent cultures were refreshed from frozen stocks.
Cell treatments
The synthetic rexinoid LG268 was kindly provided by Ligand
Pharmaceuticals (San Diego, CA, USA). LG268 and the
PPAR ligands rosiglitazone and GW-9662 were solubilized
in dimethylsulfoxide, stored in 10 M aliquots at -20°C, and
added to culture media at varying concentrations. Recombinant human IL-1 (Promega Corporation, Madison, WI,
USA) was solubilized in sterile H2O, stored in 10 g/mL aliquots at -80°C, and added to media at 1 ng/mL. For most experiments, SW-1353 cells were grown to approximately 90%
confluence in six-well plates and washed twice with HBSS to
remove trace serum and waste metabolites. Two milliliters of
serum-free DMEM supplemented with 0.2% lactalbumin
hydrosylate (DMEM/LH) and appropriate concentrations of
LG268 and/or rosiglitazone were added for 1 to 24 hours. IL1 was then added to the media for an additional 1 to 24 hours
followed by cell harvest.
Quantitative real-time reverse transcription-polymerase
chain reaction
After experimental treatment, the cells were washed twice with
cold 1× phosphate-buffered saline (PBS), scraped off the
plate, and homogenized using QIAshredder spin columns
(Qiagen Inc., Valencia, CA, USA). Total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen Inc.) in accordance
with the manufacturer's instructions, including DNA contamination removal by on-column treatment with the RNase-Free
DNase Kit (Qiagen Inc.). The reverse transcription (RT) reaction was performed on 4 g of purified total RNA using Moloney murine leukemia virus reverse transcriptase (Invitrogen
Corporation, Carlsbad, CA, USA) with oligo(dT) or random
hexamer primers (Applied Biosystems, Foster City, CA, USA)
for mRNA and heterogeneous nuclear RNA (hnRNA) studies,
respectively. The RT reactions were performed in a PTC-100
thermal cycler (MJ Research, now part of Bio-Rad Laboratories, Inc., Hercules, CA, USA). Real-time polymerase chain
reaction (PCR) was performed using the SYBR Green PCR
Master Mix kit (Applied Biosystems) in accordance with the
manufacturer's instructions. PCRs were run with experimental
triplicates and machine (on-plate) duplicates or triplicates for
each sample. To enable quantitative between-plate comparisons, standard curves were generated with each mRNA
assay. Both experimental and standard reactions were run
using 125 ng each of the appropriate forward and reverse
primers for the MMPs analyzed (sequences described previously in [21]). Target gene expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA
expression and reported as mean copies ± standard deviation
of target gene mRNA per copy of GAPDH mRNA. Several
real-time RT-PCR experiments in which standard curve plasmids were not available were performed. In these cases, the
relative mRNA levels of the experimental gene under different
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treatment conditions were normalized to GAPDH mRNA levels using the 2-Ct statistical method [29].
Western blotting
Trichloracetic acid (TCA) protein precipitation and Western
blotting were performed as described previously [21]. Briefly,
SW-1353 cells were grown to confluency in six-well plates in
DMEM with 10% FBS. The media were aspirated, the cells
were washed with HBSS, and 2 mL of DMEM/LH was added
to each well. Cells were pretreated for 24 hours with rosiglitazone, LG268, or both, and IL-1 was added for an additional
24 hours. Protein was TCA-precipitated from 1 mL of media
from each well and resuspended in 40 mL of Laemmli buffer.
Samples were resolved using Tris-HEPES-SDS precast 10%
polyacrylamide gels (catalog number 25201; Pierce, Rockford, IL, USA) and transferred to an Immobilon-P polyvinylidene difluoride membrane (Millipore Corporation, Billerica,
MA, USA). The membranes were probed for MMP-1 using a
polyclonal rabbit anti-human MMP-1 antibody (AB8105;
Chemicon International, Temecula, CA, USA) or for MMP-13
with a polyclonal MMP-13 antibody generously provided by
Peter Mitchell (Pfizer Inc, New York, NY, USA). Protein bands
were visualized by incubation with a goat anti-rabbit secondary
antibody conjugated to horseradish peroxidase (Cell Signaling
Technology, Inc., Danvers, MA, USA) and enhanced chemiluminescence analysis with the Western Lightning reagent
(PerkinElmer Life and Analytical Sciences, Inc., Waltham, MA,
USA).
Collagen degradation assay
This assay was performed as previously described [21,30].
Briefly, fibrillar collagen preparations were made from Vitrogen
100 bovine type I collagen (Cohesion Technologies, Inc., Palo
Alto, CA, USA) in accordance with the manufacturer's instructions. The collagen solution was diluted to 2 mg/mL and the
pH was adjusted to 7.3 ± 0.2. Once neutralized, an equivalent
volume of DMEM/LH containing SW-1353 cells was added,
resulting in a final collagen concentration of 1 mg/mL and 2.5
× 105 cells per well of a six-well plate. Rosiglitazone, LG268,
or both were added to the collagen/cell suspension of specific
experimental wells. Following incubation at 37°C for 60 minutes, the collagen gelled and 1 mL of DMEM/LH was added
on top of the cell-containing collagen plug. After 24 hours of
incubation in DMEM/LH, IL-1 was added to the media to
induce MMP production and subsequent collagen degradation. Approximately 24 hours after the addition of IL-1, the
media were removed from each well and weighed to quantify
the extent of collagen degradation.
Luciferase reporter assays
Luciferase reporter plasmids incorporating four copies of the
putative overlapping DR-1/AP-1 site of the MMP-1 (MMP1ENDOG-Luc) or MMP-13 (MMP13-ENDOG-Luc) promoters
were constructed using the pGL3-basic plasmid (Promega
Corporation). Control reporters were constructed in a similar
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fashion, with four scrambled copies of the DR-1/AP-1 element
of MMP-1 (MMP1-SCRAM-Luc) or MMP-13 (MMP13SCRAM-Luc). SW-1353 cells were plated in six-well plates at
a density of 1.5 × 105 cells per well. The next day, cells were
transiently transfected in six-well plates with 2 g/well of the
PPRE-tk-luciferase plasmid [31], or the custom DR-1/AP-1luciferase plasmids described above, using 5 L/well of Lipofectamine 2000 (Invitrogen Corporation) in accordance with
the manufacturer's instructions. Four to six hours after transfection, cells were washed twice with HBSS followed by the
addition of 2 mL of DMEM/LH media containing the indicated
NHR ligand. After 24 hours of ligand treatment, IL-1 was
added to the media for an additional 24 hours. The cells were
then washed three times with cold 1× PBS, and lysates were
harvested using 1× Passive Lysis Buffer (Promega Corporation). Protein concentration was determined using Bio-Rad
Protein Assay reagent (Bio-Rad Laboratories, Inc.), and equal
amounts of total protein were loaded for each sample. Luciferase activity was measured in relative light units using an
Lmax II luminometer (Molecular Devices Corporation, Sunnyvale, CA, USA).
Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) protocol was
adapted from the 'fast ChIP method' [32]. SW-1353 cells
were grown to confluence in 150-mm plates (approximately
107 cells). Crosslinking was performed by adding 40 L of
37% formaldehyde per milliliter of cell culture media directly to
the culture media, and the plates were rocked gently at room
temperature for 10 minutes. Crosslinking was quenched by
adding 141 L of 1 M glycine per milliliter media and gently
rocking for 5 minutes at room temperature. Cells were washed
twice with ice-cold 1 × PBS, scraped, and collected in 15-mL
conical tubes on ice. Cells were pelleted by centrifugation at
2,000 g for 5 minutes at 4°C, resuspended in 1 mL of ChIP
buffer (150 mM NaCl, 50 mM Tris HCl pH 7.5, 5 mM EDTA
[ethylenediaminetetraacetic acid], 0.5% NP40, 1% Triton X100) with protease inhibitors (complete mini tabs; Roche, Nutley NJ, USA), and lysed on ice for 10 minutes. Nuclei were collected by centrifugation at 12,000 g for 1 minute at 4°C and
then washed twice by aspirating the supernatant and resuspending with 1 mL of ChIP buffer. Chromatin was sonicated
on ice with 15 × 15 second pulses at power setting #40 on a
Sonics Vibro-Cell VC 130PB-1 ultrasonoic processor (Newtown, CT. USA). Debris was cleared by centrifugation at
12,000 g for 10 minutes at 4°C, and the supernatant was split
into 200-L aliquots in 1.5-mL microcentrifuge tubes for
immunoprecipitation (IP). Two micrograms of specific antibodies to the HA epitope tag (Abcam, Cambridge, UK), acetylated
histone H4 (Upstate, now part of Millipore Corporation),
PPAR (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), or normal IgG was added to each tube, and tubes were
rotated overnight at 4°C. Twenty microliters of protein A/G
agarose (Santa Cruz Biotechnology, Inc.) per IP was washed
three times, resuspended 1:1 with ChIP buffer, and distributed
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(40 L per IP) to 1.5-mL microcentrifuge tubes. IP reactions
were centrifuged at 12,000 g for 10 minutes at 4°C, and then
180 L of supernatant was transferred to the protein A/G agarose tubes and rotated for 45 minutes at 4°C. Beads were collected by centrifugation at 2,000 g for 30 seconds at 4°C and
then washed five times by removing the supernatant and
resuspending in ice-cold ChIP buffer. After washing, the pellet
was resuspended in 100 L of 10% Chelex-100 (Fisher Scientific Co., Pittsburgh, PA, USA), boiled for 10 minutes, and
then cooled on ice. One microliter of proteinase K (20 g/L)
was added to the cooled solution, vortexed, incubated at 55°C
for 30 minutes, boiled for 10 minutes, and centrifuged at
12,000 g for 1 minute. Eighty microliters of supernatant was
transferred to a new microcentrifuge tube, and 120 L of
water was added back to the original tube, vortexed, and centrifuged as before, and 120 L of supernatant was transferred
to the previous 80 L. Samples were stored at -20°C or immediately quantified using real-time PCR with primers flanking the
DR-1/AP-1 site or with negative-control primers flanking an
upstream control region (-3 kb for MMP-1 and -1 kb for MMP13), normalized to IgG-precipitated DNA, and expressed as a
fold-change over untreated cells.

anchoring of PPAR and associated corepressor complexes
at a target gene promoter, whereby pretreatment with rosiglitazone prevents the clearance of corepressor complexes by
inflammatory stimuli ([14] and see Discussion). Real-time RTPCR was used to quantify MMP mRNA, and Figure 1 demonstrates a dose-dependent inhibition of MMP-1 and MMP-13
mRNA levels in response to rosiglitazone treatment. Significant inhibition of IL-1-induced MMP-1 and MMP-13 is seen
with 10 nM rosiglitazone, with maximal inhibition at approximately 50 nM. The maximum expression of MMP-1 and MMP13 mRNA with rosiglitazone treatment is approximately 50%
of that seen with IL-1 alone, paralleling results obtained with
LG268 [21].
Next, we investigated the specificity of rosiglitazone inhibition
against a panel of MMPs. This panel included MMPs that are
responsive to IL-1 stimulation (MMP-1, MMP-3, MMP-9, and
MMP-13) as well as those that are constitutively expressed in
Figure 1

Immunoprecipitation
For the SUMO IP experiments, cellular proteins were immunoprecipitated following the ExactaCruz system instructions from
Santa Cruz Biotechnology, Inc. Briefly, cells were grown to
confluency in 150-mm dishes and treated for 1 hour with
LG268 (50 nM) and/or rosiglitazone (50 nM) in serum-free
DMEM/LH media. The cells were then treated with 1 ng/mL IL1 for 1 hour and harvested using cold radioimmunoprecipitation assay buffer. Cell lysates were homogenized using
QIAshredder columns. IP reactions were performed using 4
g of anti-SUMO-1 (Santa Cruz Biotechnology, Inc.). IP fractions were resolved using PAGE as described above. The
presence of RXR and PPAR in the IP fractions was detected
using 4 g of RXR (N197) or PPAR (H-100) antibodies
from Santa Cruz Biotechnology, Inc.

Results
Rosiglitazone inhibits MMP-1 and MMP-13 gene
expression in chondrocytic cells
The SW-1353 chondrosarcoma cell line is a model for inflammatory cytokine-induced protease production by human
chondrocytes [20,33,34], and we used these cells to quantify
the effects of rosiglitazone treatment on IL-1-stimulated levels of MMP-1 and MMP-13 mRNA. Cells were incubated for
24 hours in serum-free media containing varying doses of rosiglitazone, followed by IL-1 treatment for 24 hours. Previously, we determined that simultaneous treatment with IL-1
and LG268 leads to modest but significant inhibition of MMP1 and MMP-13, and a 12- to 24-hour pretreatment is necessary for maximum inhibition of MMP levels in these cells by the
RXR ligand, LG268 [21]. The need for pretreatment is consistent with the mechanism involving SUMOylation-dependent

13 mRNA production
Rosiglitazone
inhibits matrix
in a dose-dependent
metalloproteinase-1
manner
(MMP-1) and MMP13 mRNA production in a dose-dependent manner. SW-1353 cells
were treated with varying concentrations of rosiglitazone for 24 hours
followed by 24 hours of treatment with 1 ng/mL interleukin-1-beta (IL1). Total RNA was harvested, and MMP-1 and MMP-13 mRNA levels
were quantified using real-time reverse transcription-polymerase chain
reaction. Y values are given as molecules of MMP per molecule of
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) mRNA. There is
no statistical difference between MMP-13 mRNA levels at concentrations of 50 and 500 nM (P = 0.16). P values were calculated for the difference from the IL-1 sample using the Student t test (*P < 0.05, **P
< 0.005). NoTx, no treatment; Rosi, rosiglitazone.
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these cells (MMP-2 and MMP-14). Cells were treated with 50
nM rosiglitazone for 24 hours before stimulation with IL-1.
Using real-time RT-PCR analysis, we observed that rosiglitazone treatment significantly inhibited IL-1 induction of MMP1 and MMP-13 while having either a very modest effect
(MMP-9) or no effect (MMP-2, MMP-3, and MMP-14) on
other MMP family members (Figure 2). With rosiglitazone, both
the maximum level of inhibition of MMP-1 and MMP-13 (50%
to 60%) and the pattern of MMP inhibition mirror those previously seen with LG268 treatment [21], suggesting that these
compounds may be acting through similar mechanisms.
Combined treatment with rosiglitazone and LG268
further reduces MMP-1 and MMP-13 mRNA and hnRNA
Considering the parallel effects on MMP production with rosiglitazone and LG268 treatment and the fact that these ligands
share a molecular target (RXR:PPAR heterodimers), we

measured the effects on IL-1-induced MMP-1 and MMP-13
levels when the two ligands were added in combination. SW1353 cells were treated for 24 hours with 50 nM LG268, 50
nM rosiglitazone, or the combination of both treatments followed by IL-1 stimulation for 24 hours. As shown in Figure
3a, treatment with either LG268 or rosiglitazone effectively
reduced MMP-1 and MMP-13 mRNA by approximately 50%,
and treatment with both ligands led to significantly greater inhibition (approximately 75%) than either drug alone. This is consistent with the idea that treatment with both ligands might
increase the binding of RXR:PPAR to the DR-1 elements in
the MMP-1 and MMP-13 promoters, thereby displacing AP-1
transcription factors and causing greater inhibition of mRNA
production.
To determine whether the inhibitory effects of rosiglitazone
and the combination treatment with LG268 were due, at least

Figure 2

Matrix metalloproteinase-1 (MMP-1) and MMP-13 mRNA production is specifically inhibited by rosiglitazone treatment
treatment. SW-1353 cells were incubated with 50 nM rosiglitazone for 24 hours followed by 1 ng/mL interleukin-1-beta (IL-1) treatment for an additional 24 hours. Total RNA was harvested, and MMP mRNA levels were quantified using real-time reverse transcription-polymerase chain reaction. Y values are given as molecules of
MMP per molecule of GAPDH (glyceraldehyde 3-phosphate dehydrogenase) mRNA. P values were calculated for the difference from the IL-1 sample using the Student t test (*P < 0.05, **P < 0.005). NoTx, no treatment; Rosi, rosiglitazone.
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Figure 3

Combination treatment with LG268 and
and rosiglitazone
rosiglitazone results
results in
in increased
increasedinhibition
inhibitionof
ofmatrix
matrixmetalloproteinase-1
metalloproteinase-1(MMP-1)
(MMP-1)and
andMMP-13
MMP-13expression.
expression
SW-1353 cells were treated for 24 hours with 50 nM LG268, 50 nM rosiglitazone, or both compounds followed by 24 hours of treatment with 1 ng/
mL interleukin-1-beta (IL-1). Total RNA was harvested, and MMP (a) mRNA and (b) heterogeneous nuclear RNA levels were quantified using realtime reverse transcription-polymerase chain reaction. Y values are given as molecules of MMP per molecule of GAPDH (glyceraldehyde 3-phosphate dehydrogenase). P values above each vertical bar were determined for the difference from the IL-1 sample, and P values above the horizontal
bars were determined for the difference between samples on either end of the bar. In all cases, P values were calculated using the Student t test
(**P < 0.005, ***P < 0.0005). 268, LG100268; NoTx, no treatment; Rosi, rosiglitazone.

in part, to effects on the rate of transcription, we performed
real-time RT-PCR analysis of MMP-1 and MMP-13 hnRNA
levels [21,34,35]. Similar to the mRNA results, treatment with
LG268 or rosiglitazone alone resulted in equivalent decreases
in IL-1-stimulated MMP-1 and MMP-13 hnRNA levels (Figure
3b), indicating an effect at the transcriptional level. With combined treatment, hnRNA levels for both MMP-1 and MMP-13
were significantly lower when compared with cells treated with
a single compound, paralleling the effects seen on mRNA. This
inhibition with combined treatment appears to be additive,
again suggesting that the compounds may be acting through
similar mechanisms.
Rosiglitazone and LG268 inhibit MMP-1 and MMP-13
protein production and collagen destruction by SW-1353
cells
Figure 3 shows a decrease in expression of MMP-1 and MMP13 at the transcriptional level in cells treated with LG268 and
rosiglitazone. To determine whether this inhibition extended to
the level of MMP protein production and enzymatic activity, we
performed Western blot analysis of MMP-1 and MMP-13 protein levels in conditioned media and an in vitro collagen
destruction assay looking at the breakdown of type I collagen
matrix by IL-1-stimulated SW-1353 cells [30,36]. A marked
increase in MMP-1 and MMP-13 protein was detected in IL1-treated cells (Figure 4a, lane 2). Pretreatment with rosigli-

tazone or LG268 reduced the amount of MMP-1 and MMP13 protein detected (Figure 4a, lanes 6 and 7), and combined
pretreatment with rosiglitazone and LG268 together had a
greater effect than either compound alone (Figure 4a, lane 8).
In the collagen destruction assay, after treatment with LG268
and rosiglitazone either alone or together for 24 hours, IL-1
was added for an additional 24 hours and liberated culture
media that had been trapped within the collagen matrix were
harvested and quantified by weighing [30,36]. Figure 4b
shows that treating the cells with IL-1 resulted in substantial
destruction of the collagen matrix, as indicated by the liberation of medium trapped within the matrix. The figure also
shows that either LG268 or rosiglitazone decreased collagen
destruction by IL-1-stimulated SW-1353 cells by approximately 50% to 60%. When the drugs were added together,
there was even less collagen breakdown than that seen with a
single compound, resulting in only 20% of the matrix degradation seen with IL-1 alone. This finding indicates that dual
treatment with rexinoids and PPAR ligands may be an attractive avenue of investigation for the therapeutic inhibition of collagen destruction in arthritis (see Discussion).
Rosiglitazone and LG268 transactivate a PPRE
The previous figures show that LG268 and rosiglitazone have
an inhibitory effect on both the production and activity of
MMP-1 and MMP-13 in IL-1-stimulated chondrocytic cells.

Page 7 of 16
(page number not for citation purposes)

Arthritis Research & Therapy

Vol 10 No 6

Burrage et al.

Figure 4
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rosiglitazone (a) SW-1353 cells were pretreated
for 24 hours in serum-free media with 50 nM LG268, 50 nM rosiglitazone, or both, followed by treatment with interleukin-1-beta (IL-1) for 24 hours.
Protein was trichloracetic acid-precipitated from 1 mL of the conditioned media and resuspended in 40 L of Laemmli buffer, and the entire sample
was resolved using Tris-HEPES-SDS-PAGE and then transferred to a polyvinylidene difluoride membrane that was probed with anti-MMP-1 or antiMMP-13 antibodies. (b) SW-1353 cells were embedded in a type I collagen matrix diluted to 1 mg/mL with serum-free media containing 50 nM
LG268, 50 nM rosiglitazone, or both compounds. After gelation of the collagen, an additional 1 mL of serum-free media containing 50 nM LG268,
50 nM rosiglitazone, or both compounds was added on top of the gelled collagen and allowed to incubate for 24 hours. IL-1 was then added to the
media to stimulate MMP production, and after 24 hours the media was recovered and quantified. Collagen breakdown is indicated by media quantities over 1 g, with the additional media being released from the collagen gel during destruction. Y values are the amount of media recovered over 1
mL. P values were calculated for the difference from the IL-1-treated sample using the Student t test (*P < 0.05, **P < 0.005, ***P < 0.0005). 268,
LG100268; MMP, matrix metalloproteinase; NoTx, no treatment; Rosi, rosiglitazone.

We next wanted to investigate the possible mechanisms
behind this inhibition. RXR:PPAR heterodimers can regulate
gene expression through binding to PPRE/DR-1 sites in the
promoters of target genes [37]. Therefore, to determine
whether RXR:PPAR heterodimers function as expected in the
SW-1353 cell line, we used a luciferase reporter assay to test
the response of a canonical PPRE/DR-1 element to treatment
with rosiglitazone and LG268. We obtained a luciferase
reporter construct, driven by three copies of the consensus
PPRE from the rat acyl-CoA oxidase promoter, which is known
to be activated by treatment with PPAR and RXR ligands
[31]. SW-1353 cells were transfected with the reporter construct and then treated with LG268 and rosiglitazone either
alone or together for 24 hours. The cells were then treated
with IL-1 for an additional 24 hours and cell lysates were
assayed for luciferase activity. Figure 5a demonstrates that
treatment with either LG268 or rosiglitazone led to an approximately twofold increase in luciferase levels as compared with
untreated cells, and treatment with both drugs led to even
greater activation, approximately fourfold over untreated cells.
The addition of IL-1 appeared to have minimal effect on
reporter expression. These findings support the conclusions
that (a) LG268 and rosiglitazone are each able to activate a
consensus PPRE/DR-1 element in the SW-1353 cells and (b)
combination treatment leads to synergistic activation of this
element, presumably because both partners of the
RXR:PPAR heterodimer are liganded/activated.
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Rosiglitazone and LG268 fail to transactivate the DR-1/
AP-1 element
After demonstrating that a canonical PPRE/DR-1 reporter
construct responded as expected, we reasoned that if
RXR:PPAR were binding to the DR-1/AP-1 site in the MMP1 and MMP-13 proximal promoters, this DNA element may
also be responsive to treatment with combinations of LG268
and rosiglitazone. We used a luciferase reporter assay with a
construct driven by four copies of the endogenous DR-1/AP1 element from either the MMP-1 or MMP-13 promoter. Figure 5b shows that neither the MMP-1 (MMP1-ENDOG-Luc)
nor the MMP-13 (MMP13-ENDOG-Luc) construct was
responsive to treatment with rosiglitazone or LG268. The figure also shows that treatment with IL-1 reduced expression
of both constructs, which does not reflect the response of
endogenous MMP-1 and MMP-13, whose expression is
induced by IL-1 (Figures 1 and 3). Previous studies have
shown that reporter gene expression driven by components of
the MMP-1 and MMP-13 promoters often do not mirror
expression of the endogenous genes [20,21]. Although Figure
5 suggests that the putative DR-1 element of the DR-1/AP-1
site does not function as a traditional response element for
RXR:PPAR in these cells, the paradoxical response to IL-1
led us to abandon further studies with the DR-1/AP-1 luciferase constructs in favor of a more direct, in vivo approach,
illustrated by the ChIP studies (see below). Taken together,
the luciferase reporter data suggest that mechanisms requir-
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Figure 5

Rosiglitazone
tein-1
(DR-1/AP-1)
and LG268
reporters
activate a consensus PPRE-luciferase reporter but not the matrix metalloproteinase (MMP) direct repeat-1/activator protein-1 (DR-1/AP-1) reporters. SW-1353 cells were seeded in six-well plates and transfected with 2 g/well of the (a) PPRE-Luc, (b) MMP1ENDOG-Luc, or MMP13-ENDOG-Luc (see Materials and methods) luciferase reporter constructs and then treated for 24 hours with 50 nM LG268,
50 nM rosiglitazone, or both drugs together, followed by no treatment or 1 ng/mL interleukin-1-beta (IL-1) for 24 hours. Cells were solubilized in
passive lysis buffer, and equal amounts of protein were loaded for each sample and assayed for luciferase activity as reported in relative light units
(RLU). Error bars represent standard deviations of biological triplicates. P values were calculated using the Student t test (*P < 0.05, **P < 0.005,
***P < 0.0005). In (a), there was no statistical difference (P > 0.2) between the nuclear receptor ligand-treated samples and their corresponding IL1-treated counterparts (for example, rosiglitazone versus rosiglitazone + IL-1). In (b), P values represent the IL-1-treated group versus the non-IL1-treated group. 268, LG100268; NoTx, no treatment; PPRE, peroxisome proliferator-activated receptor-gamma response element; Rosi, rosiglitazone.

ing native chromatin conformation are involved in regulating
expression of these genes, including histone modification
([21] and see below) and interaction with factors at other promoter elements [20,21].
Treatment with IL-1, but not rosiglitazone or LG268,
correlates with an increase in PPAR at the DR-1/AP-1
site
If LG268 and rosiglitazone increase the affinity of RXR:PPAR
binding to the DR-1/AP-1 site, thereby interfering with binding
to that site by the AP-1 transcription factors, then elevated levels of PPAR would be expected at the DR-1/AP-1 site in cells
treated with LG268 and rosiglitazone when compared with
cells treated with IL-1 alone. In that regard, we used ChIP
assays to test whether endogenous PPAR was detectable at
the DR-1/AP-1 sites in the MMP-1 and MMP-13 promoters.
SW-1353 cells were treated with rosiglitazone, LG268, or
both, with or without IL-1. Sonicated chromatin was immunoprecipitated with anti-PPAR antibody (catalog number sc-

7196 X; Santa Cruz Biotechnology, Inc.) and the enriched
DNA was quantified with real-time PCR using primers targeting the DR-1/AP-1 sites of MMP-1 and MMP-13 or a nonspecific upstream region of the promoter as a negative control
(see Materials and methods). The data in Figure 6 are representative of at least three independent experiments. We
detected a marked increase in PPAR at the DR-1/AP-1 site
at both promoters in cells treated with IL-1, which appeared
to be blocked by ligand treatment at the MMP-1 promoter but
only modestly inhibited at the MMP-13 promoter (Figure 6).
We saw little effect when rosiglitazone or LG268 was added
alone. For all conditions, there was little variation at the
upstream control region, demonstrating localization of
changes in PPAR binding at the target site. We also performed these experiments in SW-1353 cells transiently transfected with a plasmid expressing hemagglutinin-tagged
PPAR (HA-PPAR). Endogenous MMP-1 and MMP-13
mRNA expression was unaffected by the overexpression of
HA-PPAR and responded as seen previously to rosiglitazone,
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Figure 6
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receptor-gamma (PPAR) at the matrix metalloproteinase-1 (MMP-1) and MMP-13 direct repeat-1/activator protein-1 (DR-1/AP-1) site. SW-1353 cells were treated for 24 hours with 50 nM
LG268, 50 nM rosiglitazone, or both, followed by no treatment or 1 ng/mL IL-1 for 24 hours. Cells were crosslinked with formaldehyde, and nuclei
were collected and sonicated to shear chromatin to an average length of 500 base pairs. The crosslinked sonicated chromatin was immunoprecipitated overnight with an antibody to PPAR and pulled down with protein A/G agarose beads. The immunoprecipitated DNA was treated with Chelex
100 beads followed by proteinase K and used in real-time polymerase chain reaction with primers flanking the DR-1/AP-1 site of MMP-1 or MMP13 or with negative-control primers flanking a region of DNA -3 kb upstream from the DR-1/AP-1 in MMP-1 or -1 kb upstream for MMP-13. Data
were normalized to nonspecific IgG-precipitated DNA and expressed as fold-change over untreated cells. Results are representative of at least three
independent experiments. 268, LG100268; NoTx, no treatment; Rosi, rosiglitazone.

LG268, and IL-1, as measured by real-time RT-PCR (data not
shown). We immunoprecipitated with an antibody to the HA
tag and saw similar results (Figure 7). The unexpected
increase in PPAR with IL-1 treatment may suggest a potential role for PPAR in IL-1 signaling at the DR-1/AP-1 element
in the MMP-1 and MMP-13 promoters (see Discussion). We
concluded that these findings do not support the competitive
binding model, in which one would expect to see an increase
in PPAR at the DR-1/AP-1 site with rosiglitazone or LG268
treatment as compared with treatment with IL-1 alone.
IL-1-induced histone acetylation is inhibited by
rosiglitazone and LG268
RXR:PPAR is known to affect the transcription of target
genes via interaction with coactivator and corepressor complexes that modify histones in the target gene promoter by
acetylating and deacetylating core histone subunits, including
histone subunit H4 [12]. LG268 has been shown to prevent
histone acetylation at the proximal promoter region of both
MMP-1 and MMP-13 in IL-1-treated SW-1353 cells [21].
We used ChIP assays, as described above, with antibodies to
acetylated histone H4 to detect changes in acetylation of histones at the DR-1/AP-1 element in both MMP-1 and MMP-13
promoters in SW-1353 cells treated with rosiglitazone,
LG268, or both, with or without IL-1. At the DR-1/AP-1 element in both promoters, IL-1 treatment led to a marked
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increase in histone acetylation (Figure 8), consistent with HAT
recruitment, H4 acetylation, and subsequent transcriptional
activation [13]. This increase in acetylation was blocked by
treatment with either rosiglitazone or LG268, consistent with
the recruitment of HDACs and subsequent transcriptional
repression [13]. Importantly, combined treatment with rosiglitazone and LG268 led to a dramatic decrease in H4 acetylation at both the MMP-1 and MMP-13 promoters, suggesting
that decreased acetylation may be a prominent mechanism by
which these two ligands decrease transcriptional activity of
these genes (see Discussion). We also note that, as seen previously in Figure 6, there was little variation at the upstream
control region, demonstrating localization of alterations in H4
acetylation to the DR-1/AP-1 site. These data, considered with
the PPAR ChIP results (Figures 6 and 7), suggest that rosiglitazone and LG268 may be inhibiting the IL-1-induced transcription of MMP-1 and MMP-13 not by a physical blockade
of factor binding but through a mechanism involving interaction with HDAC-containing coregulatory complexes and regulation of histone acetylation [12].
Treatment with rosiglitazone and LG268 leads to
SUMOylation of PPAR and RXR
Maximum inhibition of IL-1-induced MMP-1 and MMP-13
expression by LG268 requires 12 to 24 hours of pretreatment
with LG268 prior to the addition of IL-1 [21], and we see a
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Figure 7

Hemagglutinin-tagged peroxisome proliferator-activated receptor-gamma (HA-PPAR) chromatin immunoprecipitation (ChIP)
(ChIP). SW-1353 cells were
transiently transfected with a construct expressing HA-PPAR and treated for 24 hours with 50 nM LG268, 50 nM rosiglitazone, or both, followed by
no treatment or 1 ng/mL interleukin-1-beta (IL-1) for 24 hours. Cells were crosslinked with formaldehyde, and nuclei were collected and sonicated
to shear chromatin to an average length of 500 base pairs. The crosslinked sonicated chromatin was immunoprecipitated overnight with an antibody
to the hemagglutinin tag and pulled down with protein A/G agarose beads. The immunoprecipitated DNA was treated with Chelex 100 beads followed by proteinase K and used in real-time polymerase chain reaction with primers flanking the direct repeat-1/activator protein-1 (DR-1/AP-1) site
of matrix metalloproteinase-1 (MMP-1) or MMP-13 or with negative-control primers flanking a region of DNA -3 kb upstream from the DR-1/AP-1 in
MMP-1 or -1 kb upstream for MMP-13. Data were normalized to nonspecific IgG-precipitated DNA and expressed as fold-change over untreated
cells. Results are representative of at least three independent experiments. 268, LG100268; NoTx, no treatment; PPAR, peroxisome proliferatoractivated receptor-gamma; Rosi, rosiglitazone.

similar requirement for pretreatment with rosiglitazone (data
not shown). A mechanism of SUMOylation-dependent inhibition of inflammatory gene expression by PPAR, proposed by
Pascual and colleagues [14], suggested a possible explanation for the necessity of pretreatment described above. In their
model, SUMOylation of PPAR anchors the nuclear receptor
at the target gene promoter and prevents the clearance of
associated corepressors by proinflammatory stimuli [14].
Therefore, we sought to determine whether LG268 and rosiglitazone could cause SUMOylation of RXR and PPAR in SW1353 cells. We treated SW-1353 cells with LG268, rosiglitazone, or both compounds for 1 hour, followed by no additional
treatment or by IL-1 stimulation for 1 hour. Cell lysates were
harvested and total cellular protein was subjected to IP with an
antibody against SUMO-1. We then probed the immunoprecipitated fractions for RXR or PPAR using Western blotting.
Figure 9a demonstrates that SW-1353 cells contain a minimal
amount of singly SUMOylated PPAR (molecular weight 82
kDa) and that treatment with IL-1 alone may slightly increase
this level (lanes 1P and 2P). However, the presence of rosiglitazone induced a higher molecular weight form of the
SUMOylated receptor (lanes 4P and 5P). The molecular
weight of the induced band is approximately 115 kDa, which
suggests that it is a doubly SUMO1-ylated form of PPAR.
Surprisingly, treatment with LG268 alone (lane 3P) also

caused a modest increase in doubly SUMOylated PPAR, similar to that induced by rosiglitazone (lane 4P). This suggests
two conclusions: (a) LG268 treatment alone induces a
SUMOylated form of PPAR, which may transrepress inflammatory genes, and (b) liganding one receptor in the heterodimer can cause SUMOylation of the unliganded partner
(for example, liganded RXR causes the SUMOylation of unliganded PPAR). Interestingly, IL-1 treatment partially
decreases the levels of the doubly SUMOylated receptor in all
pretreatment groups (lanes 6P, 7P, and 8P), suggesting that
proinflammatory stimuli may negatively regulate ligandinduced SUMOylation of PPAR (see Discussion).
We next investigated whether the rexinoid LG268 similarly
affected the SUMOylation state of its receptor target, RXR,
which has been shown to be a target of SUMOylation [28].
We performed the same Western blot/IP analysis as
described above, with the exception of Western blotting with
anti-RXR antibody. As shown in Figure 9b, no SUMOylated
RXR is present in untreated cells or in cells treated with IL-1
(lanes 1R and 2R). However, treatment with LG268 led to
modest increases in both a low- and high-molecular weight
forms of SUMO1-RXR (lane 3R).
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Figure 8

Rosiglitazone and LG268 block interleukin-1-beta (IL-1)-induced histone acetylation at the direct repeat-1/activator protein-1 (DR-1/AP-1) site.
site
SW-1353 cells were treated for 24 hours with 50 nM LG268, 50 nM rosiglitazone, or both, followed by no treatment or 1 ng/mL IL-1 for 24 hours.
Cells were crosslinked with formaldehyde, and nuclei were collected and sonicated to shear chromatin to an average length of 500 base pairs. The
crosslinked sonicated chromatin was immunoprecipitated overnight with an antibody to acetylated histone H4 and pulled down with protein A/G
agarose beads. The immunoprecipitated DNA was treated with Chelex 100 beads followed by proteinase K and used in real-time polymerase chain
reaction with primers flanking the DR-1/AP-1 site of matrix metalloproteinase-1 (MMP_1) or MMP-13 or with negative-control primers flanking a
region of DNA -3 kb upstream from the DR-1/AP-1 in MMP-1 or -1 kb upstream for MMP-13. Data were normalized to nonspecific IgG-precipitated
DNA and expressed as fold-change over untreated cells. Results are representative of at least three independent experiments. 268, LG100268;
NoTx, no treatment; Rosi, rosiglitazone.

The figure also shows that treatment with rosiglitazone
induced a high-molecular weight form (molecular weight 115
kDa) of SUMO1-RXR (lane 4R), again likely representing
SUMO1-ylation of the receptor at multiple sites. Along with the
effect seen in lane 3P of Figure 9b, the SUMOylation of RXR
induced by rosiglitazone (lane 4R) lends additional support to
the hypothesis that the binding of ligand by one nuclear receptor may cause cross-SUMOylation of the unliganded dimer
partner. Treatment with both ligands leads to an increase in
the effects observed with single agents: a strong upper band
and a modest increase in a lower band (lane 5R). Interestingly,
when the cells are stimulated with IL-1 after ligand pretreatment, only the singly SUMO1-ylated form of RXR is seen
(lanes 6P, 7P, and 8P). This suggests that treatment with a
proinflammatory cytokine may activate pathways that cause
removal of SUMO1 from conjugated RXR or perhaps degradation of doubly SUMO1-ylated RXR (see Discussion). However, we can conclude that treatment with either LG268 or
rosiglitazone leads to the induction of SUMO1-ylated forms of
both PPAR and RXR.

Discussion
Previous work has demonstrated that the PPAR ligand rosiglitazone [17,18,38] and the RXR ligand LG268 [21] each
inhibit proinflammatory cytokine induction of MMP-1 and
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MMP-13 gene expression. In this study, we address the inhibitory effects of adding both ligands on MMP-1 and MMP-13
expression in IL-1-stimulated SW-1353 cells and investigate
the mechanisms responsible for this inhibition. We show that
rosiglitazone treatment selectively reduces MMP-1 and MMP13 mRNA and note that the pattern and magnitude of MMP
reduction parallel those seen with LG268 [21]. Additionally,
combined treatment results in greater reduction of MMP-1
and MMP-13 mRNA and hnRNA than those seen with a single
ligand. We show that the effect of combined treatment on
MMP-1 and MMP-13 is observed at the protein level, where
the addition of both ligands leads to decreased collagen
destruction by IL-1-activated SW-1353 chondrosarcoma
cells over single-ligand treatment. Our investigations into the
molecular mechanisms of this inhibition centered on the possibility of a shared mechanism since both ligands bind to the
RXR:PPAR heterodimer. We explored the role of
RXR:PPAR binding to the DR-1/AP-1 site in suppressing
MMP-1 and MMP-13 production and addressed possible
mechanisms of inhibition, including competitive binding
between RXR:PPAR and AP-1 proteins, altered histone
acetylation at the DR-1/AP-1 promoter element, and changes
in SUMOylation of PPAR and RXR.
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Figure 9
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rosiglitazone
the unliganded
induce
partner
SUMOylation of their respective
receptors and the unliganded partner. LG268 and rosiglitazone treatment increases SUMOylation of (a) peroxisome proliferator-activated
receptor-gamma (PPAR) and (b) retinoid X receptor (RXR). SW-1353
cells were treated with 1 hour of 50 nM LG268, 50 nM rosiglitazone, or
both for pretreatment and then 1 hour of 1 ng/mL interleukin-1-beta (IL1) for stimulation. Cells were harvested in 1× radioimmunoprecipitation assay lysis buffer, and total protein was quantified. Two thousand
micrograms of total cell protein and 4 g of anti-SUMO1 antibody were
used in each immunoprecipitation reaction. Immunoprecipitated proteins were resolved using PAGE; after transfer, Western blotting was
performed with anti-PPAR or anti-RXR antibody at a dilution of
1:2,000. Bands were visualized using enhanced chemiluminescence
and overnight autorad exposure. IgG bands are displayed as a loading
control. (a) Single arrowhead denotes high-molecular weight/2 ×
SUMO1-PPAR band. (b) Double arrowhead denotes high-molecular
weight/2 × SUMO1-RXR band; single arrowhead denotes low-molecular weight/1 × SUMO1-RXR band. Lane reference numbers 1P to 8P
and 1R to 8R are displayed to facilitate description in the text. IP, immunoprecipitation; LG268, LG100268; Rosi, rosiglitazone; SUMO, small
ubiquitin-like modifier; WB, Western blotting.

The competitive binding model identified binding of PPAR to
a degenerate DR-1 site as central to the inhibition of rabbit
MMP-1 by rosiglitazone, and initial evidence suggested that
the inhibition was due to competition between PPAR and AP1 for binding at the degenerate DR-1 site [17]. In keeping with
this model, we show that, in SW-1353 cells, rosiglitazone and
LG268 result in similar levels of consensus DR-1-driven
reporter activation, suggesting that treatment with each compound may increase binding to the DR-1 element. However,
we did not observe similar results with luciferase reporter constructs driven by the endogenous DR-1/AP-1 elements from
the human MMP-1 and MMP-13 promoters. These data contrast with previous studies in which IL-1-driven luciferase
reporter activity was inhibited in a dose-dependent manner by
rosiglitazone; however, those experiments were conducted in

rabbit cells transiently transfected with a luciferase construct
driven by the rabbit MMP-1 promoter [17], whereas the
present investigation uses human constructs in human cells.
Previously, we noted a discrepancy in the behavior of transiently transfected MMP-1 promoter constructs in rabbit [39]
versus human [20,21,40] cells in response to treatment with
IL-1. We attribute these differences to a more complex regulation of the human gene and emphasize the importance of
measuring expression of the endogenous gene. Since reporter
constructs driven by elements of the human MMP-1 and
MMP-13 promoters often do not mirror expression of the
endogenous genes, we shifted to a more direct, in vivo
approach, using ChIP assays to detect changes in PPAR
binding at the DR-1/AP-1 site of the endogenous MMP-1 and
MMP-13 promoters in genomic DNA.
A key aspect of the competitive binding model is mutually
exclusive binding of PPAR and AP-1 transcription factors at
the DR-1/AP-1 element, and when considering the competitive binding model, one would expect a decrease in PPAR
binding at the site in cells treated with IL-1 as compared with
rosiglitazone- or LG268-treated cells. On the contrary, ChIP
analysis using either an HA-PPAR expression construct (Figure 7) or endogenous PPAR (Figure 6) detected an increase
in PPAR at the DR-1/AP-1 sites in IL-1-treated cells, but not
rosiglitazone- or LG268-treated cells. These data are inconsistent with the competitive binding model. The large increase
in PPAR at the DR-1/AP-1 site in IL-1-treated cells was
unexpected and may indicate a novel function of PPAR in IL1 signaling at the MMP-1 and MMP-13 promoters. Other
studies have implicated IL-1 in regulating expression of
PPAR in chondrocytes, with evidence for both decreasing
and increasing PPAR expression [41,42]. IL-1 inhibits
PPAR mRNA expression in SW-1353 cells, as measured by
real-time RT-PCR (data not shown). However, this repression
does not affect expression of the PPRE luciferase reporter
construct (Figure 5). Therefore, we speculate that PPAR may
be interacting with AP-1 transcription factors at the proximal
promoter regions of MMP-1 and MMP-13. Incorporation of
PPAR in the AP-1 complex may place the nuclear receptor in
a position to more efficiently regulate AP-1-driven transcription
of MMP-1 and MMP-13. PPAR directly interacts with at least
one member of the AP-1 transcription factor family [43], and
there are examples of other NHRs directly interacting with the
AP-1 transcription factors [44-46].
As the PPAR ChIP did not appear to support the competitive
binding model, we next used ChIP to examine the MMP-1 and
MMP-13 promoters for evidence of nuclear receptor-associated coactivator and corepressor activity by detecting
changes in histone acetylation. We have previously shown that
IL-1 leads to an increase in histone acetylation at these promoters in SW-1353 cells and that this increase in acetylation
is blocked when the cells are pretreated with LG268 [21]. Our
results show that, as seen previously with LG268, treatment
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with rosiglitazone prevented histone acetylation at the DR-1/
AP-1 site in the proximal promoters of MMP-1 and MMP-13.
Most importantly, dual treatment with rosiglitazone and LG268
resulted in the additive reduction of histone acetylation at both
promoters. Given that HDAC activity is typically associated
with transcriptional repression [47], this result is consistent
with the decrease in MMP-1 and MMP-13 gene expression in
cells treated with a combination of both ligands, suggesting
that the compounds may be inhibiting expression of these
genes through a common histone acetylation-associated
mechanism.
To further investigate this mechanism, we returned to the
PPAR literature. The model describing inhibition of proinflammatory genes by a SUMOylated form of PPAR proposed by
Pascual and colleagues [14] is attractive for several reasons.
First, we are investigating the inhibition of MMPs induced by
IL-1, a prototypical inflammatory cytokine. Second, the model
requires that the SUMOylated NHR act to anchor the corepressors before they are released by proinflammatory stimuli,
possibly providing an explanation for the required pretreatment [21]. Lastly, the mechanism involves regulation via posttranslational modification of histones, which suggests that
native chromatin conformation is important for the regulation of
MMP-1 and MMP-13 and may help to explain the difficulties
seen with transiently transfected luciferase reporter constructs containing endogenous promoter sequences [20,21].
Our data show that treatment with either rosiglitazone or
LG268 induces a multiply SUMOylated form of PPAR (Figure
9a), suggesting that both compounds may work through
PPAR to inhibit proinflammatory genes. This result was rather
surprising because, in addition to confirming that a PPAR ligand can cause SUMOylation of PPAR in SW-1353 cells, it
indicates that treatment with an RXR ligand causes SUMOylation of PPAR. In addition, we show that LG268 leads to
SUMOylation of RXR. This suggests that, similar to rosiglitazone and PPAR, LG268 inhibits proinflammatory genes by
inducing a SUMOylated form of its target receptor, RXR. Interestingly, rosiglitazone also induces SUMOylation of RXR, a
result that complements our observation demonstrating
LG268-induced SUMOylation of PPAR. These data may be
explained by the fact that, when RXR and PPAR heterodimerize, they are in close proximity to one another. When the
SUMOylation machinery is recruited to the heterodimer
through the liganding of one partner, attachment of SUMO
may be a somewhat leaky process, thereby leading to
SUMOylation of the unliganded dimer partner.
Our data also suggest that, while treatment with LG268 or
rosiglitazone induces SUMOylation of RXR, the PPAR ligand
preferentially leads to a higher molecular weight form that is
consistent with a doubly SUMOylated version of the receptor.
To address this point, we analyzed the protein sequence of
RXR and have identified three putative consensus SUMOyla-
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tion sites (K201, K245, and K364). The presence of multiple
SUMOylation sites on RXR may help to explain the different
molecular weight forms of SUMOylated RXR by suggesting
that rosiglitazone induces two SUMO molecules to be added
to RXR whereas LG268 induces conjugation of only a single
SUMO molecule. Because both LG268 and rosiglitazone
inhibit IL-1-induced MMP production and only a singly
SUMOylated form of RXR persists when IL-1 is added, perhaps only one site needs to be SUMOylated to cause the
inhibitory effect. Interestingly, the K364 site in RXR is very similar in location to the K365 site in PPAR that Pascual and colleagues [14] demonstrated was required for rosiglitazonemediated inhibition. Because of the conserved nature of NHR
domain structures, K364 may be the required RXR SUMOylation site for inhibition of MMP-1 and MMP-13 through this
mechanism.

Conclusion
Our data show that the PPAR ligand rosiglitazone and the
RXR ligand LG268 specifically inhibit MMP-1 and MMP-13
gene expression in IL-1-stimulated chondrocytic cells. This
inhibition appears to be mediated through multiple mechanisms operating at a transcriptional level. Given the link
between increased MMP-1 and MMP-13 gene expression
and the arthritides, these compounds could be useful in a therapeutic setting. Clinical investigations using these drugs are
already under way in diseases such as diabetes and cancer;
rosiglitazone and another thiazolidinedione, pioglitazone, are
currently in clinical use as insulin-sensitizing agents in diabetes [48], the rexinoid bexarotene is used as a treatment for
cutaneous T-cell lymphoma [49], and there are promising data
on the use of LG268 as a chemopreventive compound for
breast cancer and lung cancer [50,51]. Combined treatment
with ligands for both RXR and PPAR leads to additive inhibition of MMP-1 and MMP-13 production, suggesting that
these compounds could be used together, in lower doses than
single-drug treatment, to reduce or block joint destruction in
arthritis, thus minimizing the risk of adverse side effects.
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